Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen

Leukemia Research

Volumn 30, Issue 8, 2006, Pages 935-942

  Zhang, Wanggang ^a   Zhou, Fuling ^a   Cao, Xinmei ^a   Cheng, Yinxia ^a   He, Aili ^a   Liu, Jie ^a   Ma, Xiaorong ^a   Chen, Gang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

All trans retinoic acid; Androgen; Calcitriol; Primary refractory anemia

Indexed keywords

CALCITRIOL; DANAZOL; RETINOIC ACID; STANOZOLOL;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GRAND MAL SEIZURE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENOSCHESIS; MENSTRUATION DISORDER; MOUTH ULCER; MYCOSIS; PARESTHESIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; XEROSIS;

ADOLESCENT; ADULT; AGED; ANDROGENS; ANEMIA, REFRACTORY; CALCITRIOL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN;

EID: 33744827689     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.11.017     Document Type: Article

References (60)

1. Cilloni D., Messa F., Carturan S., Arruga F., Defilippi I., Messa E., et al. Myelodysplastic syndromes. Ann N Y Acad Sci 1028 (2004) 400-408
2. List A.F., Vardiman J., Issa J.P., and Dewitte T.M. Myelodysplastic syndromes. Hematology 1 (2004) 297-317
3. Hofmann W.K., and Koeffler H.P. Myelodysplastic syndrome. Annu Rev Med 56 (2005) 1-16
4. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
5. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
6. Stasi R., Brunetti M., Bussa S., Conforti M., Di Giulio C., Crescenzi A., et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 3 (1997) 733-739
7. Clavio M., Balleari E., Garrone A., Ballerini F., Varaldo R., Michelis G.L., et al. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?. J Exp Clin Cancer Res 24 (2005) 5-216
8. Thompson J.E., and Luger S.M. The role of hematopoietic stem cell transplantation in myelodysplastic syndrome. Oncology (Huntingt) 19 (2005) 533-542
9. Yazji S., Giles F.J., Tsimberidou A.M., Estey E.H., Kantarjian H.M., O'Brien S.A., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17 (2003) 2101-2106
10. Bowen D., MacIlwaine L., Cavanagh J., Killick S., Culligan D., Thomson E., et al. Thalidomide therapy for low-risk Myelodysplasia. Leuk Res 29 (2005) 235-236
11. Tsiara S.N., Chaidos A., Gouva M., Christou L., Panteli K., Kapsali E., et al. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone. J Exp Clin Cancer Res 23 (2004) 47-52
12. Giagounidis A.A., Haase S., Germing U., Schlegelberger B., Wilkens L., Busche G., et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study. Ann Hematol 84 (2005) 389-394
13. Herault O., Domenech J., Georget M.T., Clement N., Colombat P., and Binet C. All-trans retinoic acid prevents apoptosis of human marrow CD34+ cells deprived of haematopoietic growth factors. Br J Haematol 118 (2002) 289-295
14. Nakajima H., Kizaki M., Sonoda A., Mori S., Harigaya K., and Ikeda Y. Retinoids (all-trans and 9-cis-retinoic acid) stimulate production of macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by human bone marrow stromal cells. Blood 84 (1994) 4107-4115
15. Paul C.C., Mahrer S., Tolbert M., Elbert B.L., Wong I., Ackerman S.J., et al. Changing the differentiation program of hematopoietic cells: retinoic acid-induced shift of eosinophilcommitted cells to neutrophils. Blood 86 (1995) 3737-3744
16. Tocci A., Parolini I., Gabbianelli M., Testa U., Luchetti L., Samoggia P., et al. Dual action of retinoic acid on human embryonic/fetal hematopoiesis: blockade of primitive progenitor proliferation and shift from multipotent/erythroid/monocytic to granulocytic differentiation program. Blood 88 (1996) 2878-2888
17. Purton L.E., Bernstein I.D., and Collins S.J. All-trans-retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood 94 (1999) 483-495
18. Purton L.E., Bernstein I.D., and Collins S.J. All-trans-retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. Blood 95 (2000) 470-477
19. Correa P.N., and Axelrad A.A. Retinyl acetate and all-transretinoic acid enhance erythroid colony formation in vitro by circulating human progenitors in an improved serum-free medium. Int J Cell Cloning 10 (1992) 286-291
20. Maurer A.B., Ganser A., Buhl R., Seipelt G., Ottmann O.G., Mentzel U., et al. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 7 (1993) 1728-1733
21. Aul C., Runde V., and Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82 (1993) 2967-2974
22. Letendre L., Levitt R., Pierre R.V., Schroeder G., Krook J.A., Mailliard J.E., et al. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol 48 (1995) 233-236
23. Stasi R., Brunetti M., Terzoli E., and Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99 5 (2002) 1578-1584
24. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 (2004) 1266-1269
25. Ferrero D., Bruno B., Pregno P., Stefani S., Larizza E., Ciravegna G., et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 20 (1996) 867-876
26. Mellibovsky L., Diez A., Perez-Vila E., Serrano S., Nacher M., Aubia J., et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100 (1998) 516-520
27. Chan G., DiVenuti G., and Miller K. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol 71 (2002) 166-171
28. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
29. Cermak J., Michalova K., Brezinova J., and Zemanova Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 27 (2003) 221-229
30. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
31. Kasper C., Zahner J., and Sayer H.G. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 128 (2002) 497-502
32. Shimamoto T., Tohyama K., Okamoto T., Uchiyama T., Mori H., Tomonaga M., et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 27 (2003) 783-788
33. Guan M., Chen S.C., Li R.S., Ge C.W., and Zhu H.L. Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12 (2004) 774-778
34. Cermak J., Vitek A., and Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 28 (2004) 551-557
35. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 19 (2005) 767-775
36. Shi J., Shao Z.H., Liu H., Bai J., Cao Y.R., He G.S., et al. Transformation of myelodysplastic syndromes into acute myeloid leukemias. Chin Med J (Engl) 117 (2004) 963-967
37. Maschek H., Gutzmer R., Choritz H., and Georgii A. Comparison of scoring systems in primary myelodysplastic syndromes. Ann Hematol 70 (1995) 301-308
38. Lorand-Metze I., Pinheiro M.P., Ribeiro E., de Paula E.V., and Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 28 (2004) 587-594
39. Sperr W.R., Wimazal F., Kundi M., Fonatsch C., Thalhammer-Scherrer R., Schernthaner G.H., et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80 (2001) 272-277
40. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120 (2003) 187-200
41. Polychronopoulou S., Panagiotou J.P., Kossiva L., Mavrou A., Anagnostou D., and Haidas S. Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. Acta Paediatr 93 (2004) 1015-1023
42. Lipschitz D.A., Udupa K.B., Milton K.Y., and Thompson C.O. Effect of age on hematopoiesis in man. Blood 63 (1984) 502-509
43. Noel P. Management of patients with myelodysplastic syndromes. Mayo Clin Proc 66 (1991) 485-497
44. Larson R.S., and Tallman M.S. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol 16 (2003) 453-461
45. Sadek I., Zayed E., Hayne O., and Fernandez L. Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone. Am J Hematol 64 (2000) 306-310
46. Arimura K., Arima N., Matsushita K., Ohtsubo H., Fujiwara H., Kukita T., et al. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 73 (2004) 17-24
47. Li X., Pu Q., Beckham C., and Deeg J.H. Expression of epidermal growth factor receptor and its relationship to apoptosis in myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi 24 (2003) 22-24
48. Suarez L., Vidriales M.B., Garcia-Larana J., Sanz G., Moreno M.J., Lopez A., et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 10 (2004) 7599-7606
49. Merchant S.H., Gonchoroff N.J., and Hutchison R.E. Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes. Cytometry 46 (2001) 28-32
50. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Dambaki C., Katrinakis G., Tsirakis G., et al. Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. J Mol Histol 35 (2004) 857-863
51. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J., and Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for anautoimmune process. Leuk Res 25 (2001) 1075-1083
52. Shen R., Xu C.G., Li L.Z., Zhang T., Qin X.M., and Li J. A study on early activation of T lymphocytes and soluble tumor necrosis factor receptor in patients with myelodysplastic syndrome. Zhonghua Nei Ke Za Zhi 42 (2003) 857-860
53. Asano Y., Maeda M., Uchida N., Yokoyama T., Osaki K., Shimoda K., et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 80 (2001) 634-638
54. Lu X.P., Fanjul A., Picard N., Shroot B., and Pfahl M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int J Cancer 80 (1999) 272-278
55. 3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16 (1996) 2653-2659
56. Satake K., Takagi E., Ishii A., Kato Y., Imagawa Y., Kimura Y., et al. Anti-tumor effect of Vitamins A and D on head and neck squamous cell carcinoma. Auris Nasus Larynx 30 (2003) 403-412
57. 3 and its analogs. Curr Drug Targets Inflamm Allergy 3 (2004) 377-393
58. Mahon B.D., Wittke A., Weaver V., and Cantorna M.T. The targets of Vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89 (2003) 922-932
59. Ahn Y.S. Efficacy of danazol in hematologic disorders. Acta Haematol 84 (1990) 122-129
60. Navarro J.F., Mora C., Macia M., and Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 61 (2002) 1537-1544